Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients

Yuriy V. Shebzukhov, Ekaterina P. Koroleva, Svetlana V. Khlgatian, Pavel V. Belousov, Ksenia E. Kuz'Mina, Boris V. Radko, Fanny Longpre, Maria A. Lagarkeva, Tatiana S. Kadachigova, Olga V. Gurova, Andrey A. Meshcheryakov, Mikhail R. Lichinitser, Alexander Knuth, Elke Jager, Dmitry V. Kuprash, Sergei A. Nedospasov

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Antibodies to cancer antigens can often be detected in the sera of patients, although the mechanism of the underlying humoral immune response is poorly understood. Using immunoscreening of tumor-derived cDNA expression libraries (SEREX), we identified human histone deacetylase 3 (HDAC3) as serologically defined antigen in colon cancer. Closely related HDAC1 and HDAC2 do not elicit humoral response in colon cancer patients. We show that the C-terminal region of HDAC3 protein lacking the homology to other Class I HDAC contains at least 3 distinct B-cell epitopes that are recognized by the serum antibodies. HDAC3 in combination with other SEREX antigens may become a useful molecular biomarker with diagnostic or prognostic value for a subset of colon cancer patients. (Supplementary material for this article can be found on the International Journal of Cancer website at http://www. jpages/0020-7136/suppmat/index.html).

Original languageEnglish (US)
Pages (from-to)800-806
Number of pages7
JournalInternational Journal of Cancer
Issue number5
StatePublished - Dec 10 2005
Externally publishedYes


  • Antibodies
  • Epitopes
  • HDAC3
  • Serology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients'. Together they form a unique fingerprint.

Cite this